274 related articles for article (PubMed ID: 37169935)
1. The heterogeneity of Parkinson's disease.
Wüllner U; Borghammer P; Choe CU; Csoti I; Falkenburger B; Gasser T; Lingor P; Riederer P
J Neural Transm (Vienna); 2023 Jun; 130(6):827-838. PubMed ID: 37169935
[TBL] [Abstract][Full Text] [Related]
2. Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson's disease.
Riederer P; Nagatsu T; Youdim MBH; Wulf M; Dijkstra JM; Sian-Huelsmann J
J Neural Transm (Vienna); 2023 May; 130(5):627-646. PubMed ID: 37062012
[TBL] [Abstract][Full Text] [Related]
3. Expression of α-synuclein is regulated in a neuronal cell type-dependent manner.
Taguchi K; Watanabe Y; Tsujimura A; Tanaka M
Anat Sci Int; 2019 Jan; 94(1):11-22. PubMed ID: 30362073
[TBL] [Abstract][Full Text] [Related]
4. Α-synuclein misfolding and Parkinson's disease.
Breydo L; Wu JW; Uversky VN
Biochim Biophys Acta; 2012 Feb; 1822(2):261-85. PubMed ID: 22024360
[TBL] [Abstract][Full Text] [Related]
5. α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies.
Henderson MX; Trojanowski JQ; Lee VM
Neurosci Lett; 2019 Sep; 709():134316. PubMed ID: 31170426
[TBL] [Abstract][Full Text] [Related]
6. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
Mehra S; Sahay S; Maji SK
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
[TBL] [Abstract][Full Text] [Related]
7. Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive element.
Olivares D; Huang X; Branden L; Greig NH; Rogers JT
Int J Mol Sci; 2009 Mar; 10(3):1226-60. PubMed ID: 19399246
[TBL] [Abstract][Full Text] [Related]
8. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
Schulz-Schaeffer WJ
Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
[TBL] [Abstract][Full Text] [Related]
9. Targeting α-synuclein for PD Therapeutics: A Pursuit on All Fronts.
Teil M; Arotcarena ML; Faggiani E; Laferriere F; Bezard E; Dehay B
Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32138193
[TBL] [Abstract][Full Text] [Related]
10. Therapeutics in the Pipeline Targeting
Grosso Jasutkar H; Oh SE; Mouradian MM
Pharmacol Rev; 2022 Jan; 74(1):207-237. PubMed ID: 35017177
[TBL] [Abstract][Full Text] [Related]
11. Parkinson's disease and alpha-synucleinopathies: from arising pathways to therapeutic challenge.
Miraglia F; Betti L; Palego L; Giannaccini G
Cent Nerv Syst Agents Med Chem; 2015; 15(2):109-16. PubMed ID: 25896035
[TBL] [Abstract][Full Text] [Related]
12. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
13. alpha-Synucleinopathy in the human olfactory system in Parkinson's disease: involvement of calcium-binding protein- and substance P-positive cells.
Ubeda-Bañon I; Saiz-Sanchez D; de la Rosa-Prieto C; Argandoña-Palacios L; Garcia-Muñozguren S; Martinez-Marcos A
Acta Neuropathol; 2010 Jun; 119(6):723-35. PubMed ID: 20383714
[TBL] [Abstract][Full Text] [Related]
14. Targeting α-synuclein aggregation and its role in mitochondrial dysfunction in Parkinson's disease.
Haque ME; Akther M; Azam S; Kim IS; Lin Y; Lee YH; Choi DK
Br J Pharmacol; 2022 Jan; 179(1):23-45. PubMed ID: 34528272
[TBL] [Abstract][Full Text] [Related]
15. Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson's disease patients.
Recasens A; Carballo-Carbajal I; Parent A; Bové J; Gelpi E; Tolosa E; Vila M
Acta Neuropathol Commun; 2018 Feb; 6(1):8. PubMed ID: 29422109
[TBL] [Abstract][Full Text] [Related]
16. T-Cell-Driven Inflammation as a Mediator of the Gut-Brain Axis Involved in Parkinson's Disease.
Campos-Acuña J; Elgueta D; Pacheco R
Front Immunol; 2019; 10():239. PubMed ID: 30828335
[TBL] [Abstract][Full Text] [Related]
17. α-Synuclein in Parkinson's Disease: Does a Prion-Like Mechanism of Propagation from Periphery to the Brain Play a Role?
Zheng H; Shi C; Luo H; Fan L; Yang Z; Hu X; Zhang Z; Zhang S; Hu Z; Fan Y; Yang J; Mao C; Xu Y
Neuroscientist; 2021 Aug; 27(4):367-387. PubMed ID: 32729773
[TBL] [Abstract][Full Text] [Related]
18. Gelsolin co-occurs with Lewy bodies in vivo and accelerates α-synuclein aggregation in vitro.
Welander H; Bontha SV; Näsström T; Karlsson M; Nikolajeff F; Danzer K; Kostka M; Kalimo H; Lannfelt L; Ingelsson M; Bergström J
Biochem Biophys Res Commun; 2011 Aug; 412(1):32-8. PubMed ID: 21798243
[TBL] [Abstract][Full Text] [Related]
19. α-Synuclein and Lewy pathology in Parkinson's disease.
Kalia LV; Kalia SK
Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
[TBL] [Abstract][Full Text] [Related]
20. Are Therapies That Target α-Synuclein Effective at Halting Parkinson's Disease Progression? A Systematic Review.
Rodger AT; ALNasser M; Carter WG
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
